VGR
Get informed when a big investor buys or sells
+ FollowUndervalued by 25.2% based on the discounted cash flow analysis.
| Market cap | $2.36 Billion |
|---|---|
| Enterprise Value | $3.35 Billion |
| Dividend Yield | $0.80 (5.34%) |
| Earnings per Share | $1.17 |
| Beta | 1 |
| Outstanding Shares | 153,740,654 |
| P/E Ratio | 12.51 |
|---|---|
| PEG | 32.35 |
| Price to Sales | 1.67 |
| Price to Book Ratio | -3.0 |
| Enterprise Value to Revenue | 2.36 |
| Enterprise Value to EBIT | 9.43 |
| Enterprise Value to Net Income | 16 |
| Total Debt to Enterprise | 0.41 |
| Debt to Equity | -1.94 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
No data
This committee provides critical analysis and revenue estimates for all tax legislation, directly influencing the final shape and impact of tax policies (e.g., excise taxes, corporate taxes) on the tobacco industry.
This powerful committee controls taxation, including excise taxes on tobacco products and corporate tax rates, which directly and significantly impact VGR's profitability and product pricing.
This committee oversees the FDA, which is the primary federal regulator for tobacco products, impacting manufacturing, marketing, and sales directly. It also influences labor laws affecting production costs.